Enantiomerization of an atropisomeric drug

Chirality

Volumn 8, Issue 5, 1996, Pages 364-371

  Friary, Richard J ^a   Spangler, Michael ^a   Osterman, Rebecca ^a   Schulman, Lara ^a   Schwerdt, John H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

10 (3 chlorophenyl) 6,8,9,10 tetrahydrobenzo b 1,8 naphthyridin 5(7H) one; antipsoriatic agent; dynamic HPLCs; interconversion half lives; SIMUL; stereogenic axis

Indexed keywords

ANTIPSORIASIS AGENT; NAPHTHYRIDINE DERIVATIVE; SCH 40120; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; CHROMATOGRAPHY; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RACEMIC MIXTURE; SPECTROSCOPY; STEREOCHEMISTRY; STEREOISOMERISM;

EID: 0029906741     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-636X(1996)8:5<364::AID-CHIR2>3.0.CO;2-E     Document Type: Article

References (41)

1. Rauws, A.G., Groen, K. Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States. Chirality 6:72-75, 1994.
2. FDA's policy statement for the development of new stereoisomeric drugs. May, 1992, 6 pp; available from the Center for Drug Evaluation and Research, Food and Drug Administration, Executive Secretariat Staff (HFD-8), Metro Park North, Bldg. 1, 5600 Fishers Lane, Rockville, MD 20857.
3. Cahn, R.S., Ingold, C.K., Prelog, V. The specification of asymmetric configuration in organic chemistry. Experientia 12(3):81-124, 1956.
4. Testa, B. Chirality and biological activity, Chapter Two. In: Definitions and Concepts in Biochirality. New York: Alan R. Liss, Inc., 1990: 15-32.
5. Ariëns, E.J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26:663-668, 1984.
6. 5
7. Hacksell, U., Johansson, A.N., Lewander, T. Drug discovery and chirality - implications of chirality for structure-activity relationships in drug design. Drug Information Journal 28:885-890, 1994.
8. Testa, B., Trager, W.F. Racemates versus enantiomers in drug development: Dogmatism or pragmatism? Chirality 2:129-133, 1990.
9. Testa, B., Carrup, P.-A., Gal., J. The so-called "interconversion" of stereoisomeric drugs: an attempt at clarification. Chirality 5:105-111, 1993.
10. Caldwell, J. 'Chiral pharmacology' and the regulation of new drugs. Chemistry and Industry, 6 March: 176-179, 1995.
11. Casy, A.F. The Steric Factor in Medicinal Chemistry. New York: Plenum Publishing Corp., 1993:319-322.
12. Eveleigh, P., Hulme, E.C., Schudt, C., Birdsall, N.J.M. The existence of stable enantiomers of telenzepine and their stereoselective interaction with muscarinic receptor subtypes. Mol Pharmacol 35:477-483, 1989.
13. Shklovskii, I.S., Sagan, C. Intelligent Life in the Universe. New York: Dell Publishing Co., Inc., 1966:418.
14. Schurig, V., Jung, M., Scheimer, M., Klärner, F.-G. Investigation of the enantiomerization barrier of homofuran by computer simulation of interconversion profiles obtained by complexation gas chromatography. Chem. Ber. 125:1301-1303, 1992.
15. Eliel, E.L. Stereochemistry of Carbon Compounds. New York: McGraw-Hill Book Company, Inc., 1962:177.
16. Ōki, M. Recent advances in atropisomerism. Topics in Stereochemistry 14:1-81, 1983.
17. Friary, R.J., Seidl, V., Schwerdt, J.H., Cohen, M.P., Hou, D., Nafissi, M. Intramolecular transaminations of enaminones: A synthesis of fused, polycyclic, N-aryl pyridones. Tetrahedron 49:7169-7178, 1993.
18. Jackman, L.M., Sternhell, S. Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry, 2nd ed., New York: Pergamon Press, 1969:307.
19. Jung, M. Simul: A general program for the simulation of chromatograms using the theoretical plate model. QCPE Bull 12:52-53, 1992.
20. Snyder, L.R., Kirkland, J.J. Introduction to Modern Liquid Chromatography, 2nd Ed. New York: John Wiley & Sons, Inc., 1979:22-26.
21. Snyder, L.R., Glajch, J.L., Kirkland, J.J. Practical HPLC Method Development. New York: John Wiley & Sons, Inc., 1988:46-48.
22. Bürkle, W., Karfunkel, H., Schurig, V. Dynamic phenomena during enantiomer resolution by complexation gas chromatography. J. Chromatogr. 288:1-14, 1984.
23. Jung, M., Schurig, V. Determination of enantiomerization barriers by computer simulation of interconversion profiles: enantiomerization of diaziridines during chiral inclusion gas chromatography. J. Am. Chem. Soc. 114:529-534, 1994.
24. Veciana, J., Crespo, M.I. Dynamic hplc: A method for determining rate constants, energy barriers, and equilibrium constants of molecular dynamic processes. Angew. Chem., Int. Ed. Engl. 30:74-76, 1991.
25. Keller, R.A., Giddings, J.C. Multiple zones and spots in chromatography. J. Chromatogr. 3:205-220, 1960.
26. Melander, W.R., Lin, H.-J., Jacobson, J., Horváth, C. Dynamic effect of secondary equilibria in reversed-phase chromatography. J. Phys. Chem. 88:4527-4536, 1984.
27. Breitmaier, E., Voelter, W. Carbon-13 NMR Spectroscopy. New York: VCH Publishers, 1990: 128.
28. Handbook of Chemistry and Physics, 70th Ed. Boca Raton, FL: CRC Press, 1989-1990: F-78.
29. Friary, R., Billah, M., Bryant, R.W., Ganguly, A.K., Kung, T.T., Schwerdt, J.H., Seidl, V., Siegel, M.I., Smith, S.R., Watnick, A.S. Biology and synthesis of Sch 40120, an antipsoriatic agent that inhibits 5-lipoxygenation and T-cell proliferation. In: "Book of Abstracts, Part 1, Division of Medicinal Chemistry," Abstract No. 2, American Chemical Society, Washington, D.C., 1992.
30. Koo, J., McClelland, P., Scull, T., Peets, E. A double-blind evaluation of Sch 40120, 1.0% cream, a leukotriene and cytokine synthesis inhibitor in treatment of psoriasis vulgaris. Meeting of the American Academy of Dermatology, December: 1993.
31. Siegel, M., Peets, E. Preclinical and clinical results suggest Sch 40120 effectiveness in psoriasis and atopic dermatitis. Symposium Reporter, p. 5 (1993) [proceedings of a symposium sponsored by Schering-Plough International and concerning advances in dermatology, April 30-May 1, 1993, Monaco, Monte Carlo].
32. Friary, R.J., Seidl, V., Schwerdt, J.H., Chan, T.-M., Cohen, M.P., Conklin, E.R., Duelfer, T., Hou, D., Nafissi, M., Runkle, R.L., Tahbaz, P., Tiberi, R.L. Intermolecular transaminations of enaminones: A synthesis of fused, polycyclic, N-aryl pyridones. Tetrahedron 49:7179-7192, 1993.
33. Feringa, B.L., Jaer, W.F., Lange, B.d. Resolution of sterically overcrowded ethylene; a remarkable correlation between bond lengths and racemization barriers. Let. Let. 33:2887-2890, 1992.
34. Kirkland, K.M., McCombs, D.A. Changes in chiral selectivity with temperature for an ovomucoid protein-based column. J. Chromatogr. A 666:211-219, 1994.
35. Jung, M., Schurig, V. Computer simulation of three scenarios for the separation of non-racemic mixtures by chromatography on achiral stationary phases. J. Chromatogr. A 605:161-166, 1992.
36. 4 times longer before separable atropisomers became significant on the time scales of pharmaceutical development.
37. 41 Lacking any estimate of the difference in transition state energies, we have not adjusted any of our values to take these changes into account. Although halving the rate constants would double the half-lives, the prolongation would not alter our conclusions regarding the nil consequences of the 40120 chirality. On the timescale of pharmaceutical development, a half-life increase to 3.2 min at 37°C would be insignificant. Adding the RTln2 term to the Gibbs free energies of activation would increase them only by about 2%.
38. E.L. Eliel, op. cit., p. 163.
39. Mintas, M., Orhanović, Z., Jakopčić, K., Koller, H., Stühler, G., Mannschreck, A. Enantiomers of sterically hindered N-aryl-4-pyridones. Tetrahedron 41:229-233, 1985.
40. Schurig, V., Leyrer, U. Semi-preparative enantiomer separation of 1-chloro 2,2-dimethylaziridine by complexation gas chromatography - absolute configuration and barrier of inversion. Tetrahedron: Asymmetry 1:865-868, 1990.
41. 4-thiazoline-2-thiones. Nouveau Journal de Chimie 10:399-404, 1986.